Prevention of Recurrence of Clostridioides Difficile Colitis with Ursodeoxycholic Acid (UCDA) As a Supplement to Standard Therapy

Launched by MEDICAL COLLEGE OF WISCONSIN · Mar 13, 2025

Keywords

ClinConnect Summary

Prevention of Recurrence of Clostridioides Difficile Colitis with

Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy

Paraj D. Patel M.D, Daniel J. Stein, M.D, Helmut V. Ammon, MD

This proposal describes the use of UDCA as an adjunct to standard treatment of C. difficile (C. diff) colitis for the prevention of recurrence of the disease.

The Problem: C. diff colitis is a serious burden on the healthcare system. In 2011 there were close to 500,000 cases of and 29,000 deaths from C. diff. colitis reported in the US at an annual cost of 58 billion dollars \[1, 2\] Treatment cons...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Eligible patients: C. diff. toxin +ve patients \> 18 years with one or more risk factors for recurrence \[6,7\] requiring standard treatment with Flagyl, Vancomycin or fidaxomicin.
• Exclusion Criteria:
• • Life expectancy \< 6 months; fulminant colitis; ileus; decompensated liver disease; pregnancy and lactating females; Inability to give informed consent.